BlackRock Fund Advisors has recently announced that it has increased stake in TRACON Pharmaceuticals Inc (NASDAQ:TCON) by 0.04%. After grabbing 0.27 million shares, the institutional investor is now in possession of 102.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.86% having worth around $46869.0. Moreover, Geode Capital Management LLC increased its share by 57397.0 to have a control over 0.21 million shares.
TRACON Pharmaceuticals Inc (TCON) concluded trading on Thursday at a closing price of $0.20, with 4.43 million shares of worth about $0.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.95% during that period and on Thursday, January 25 the price saw a gain of about 15.38%. Currently the company’s common shares owned by public are about 31.14M shares, out of which, 26.47M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 7 times over the past 12 months. They bought 230,507 shares in 5 of the transactions. In 2 selling transactions, insiders dumped 4,764,008 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in TRACON Pharmaceuticals Inc Vanguard Extended Market Index Fu is currently holding 0.26 million shares of worth totaling $45985.0. The company recently came buying 0.0 shares which brought its stake up to 0.84% of the company’s outstanding shares. Fidelity Nasdaq Composite Index F, after buying 73317.0 shares, have now control over 0.24% of the stake in the company. It holds 54348.0 shares of worth $12830.0.
However, the stock later moved at a day high price of 0.2100, or with a gain of 15.38%. Stock saw a price change of 33.60% in past 5 days and over the past one month there was a price change of 13.46%. Year-to-date (YTD), TCON shares are showing a performance of 16.50% which decreased to -87.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $2.19 during that period. The average intraday trading volume for TRACON Pharmaceuticals Inc shares is 5.03 million. The stock is currently trading 19.76% above its 20-day simple moving average (SMA20), while that difference is up 12.33% for SMA50 and it goes to -48.63% lower than SMA200.
BlackRock Fund Advisors acquired 0.27 million shares of TRACON Pharmaceuticals Inc having value of about $46869.0. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 102.0 shares in the company valued at close to $20.4, or have control over 0.04% stake in the company. TRACON Pharmaceuticals Inc (NASDAQ: TCON) currently have 31.14M outstanding shares and institutions hold larger chunk of about 29.64% of that. Holding of mutual funds in the company is about 28.15% while other institutional holders and individual stake holders have control over 30.85% and 1.49% of the stake respectively.
The stock has a current market capitalization of $6.35M and its 3Y-monthly beta is at 0.84. It has posted earnings per share of -$0.58 in the same period. It has Quick Ratio of 0.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TCON, volatility over the week remained 13.08% while standing at 8.51% over the month.
Analysts are in expectations that TRACON Pharmaceuticals Inc (TCON) stock would likely to be making an EPS of -$0.08 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.4 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.11 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.31 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 74.58% while it is estimated to decrease by -13.21% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on April 16, 2021 offering a Buy rating for the stock and assigned a target price of $14 to it.
